Bone marrow transplant: A two-decade single centre hematology experience

Area of Science:

• Hematology
• Transplant Immunology
• Oncology

Background:

• Bone Marrow Transplant (BMT) is a critical curative therapy for adult and pediatric hematological disorders.
• The establishment of a BMT program over two decades has significantly improved patient outcomes.

Purpose of the Study:

• To review the Bone Marrow Transplant (BMT) program data from its inception until February 2023.
• To analyze the types of hematological disorders treated, transplant modalities, and patient demographics.

Main Methods:

• Retrospective review of Bone Marrow Transplant (BMT) program data.
• Analysis of over 700 patient cases undergoing BMT for diverse hematological conditions.

Main Results:

• Over 700 patients with more than 23 hematological disorders underwent BMT.
• Autologous BMT (58%) was common for Multiple Myeloma; Allogeneic BMT (42%) for Aplastic Anemia and Acute Leukemias.
• The program expanded from Matched Sibling Donor (MSD) to include Matched Unrelated Donor (MUD) and Haploidentical Donor Transplants, with 93% of allogeneic cases being MSD.

Conclusions:

• The BMT program's evolution has enabled a
• transplant for all
• approach by expanding donor options.
• Haploidentical HSCT for nonmalignant hematological disorders remains an area for development.
• Future priorities include integrating CAR T-cell therapy and other cellular therapies.